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Summary 
Two rabbits immunized with a portion of glutamate 
receptor (GluR) subunit GluR3 (amino acids 245-457) 
exhibited seizure-like behaviors, suggesting that anti- 
bodies to GluR3 may modulate neuronal excitability. 
Using whole-cell recording, rabbit GluR3 antisera were 
tested on cultured fetal mouse cortical neurons. In a 
subset of kainate-responsive neurons, miniperfusion 
of antisera and IgG evoked currents that were blocked 
by CNQX. Immunoreactivity to synthetic peptides pre- 
pared to subregions GluR3A (amino acids 245-274) 
and GluR3B (amino acids 372-395) was present in both 
rabbit sera. Peptide GluR3B, but not GluR3A, specifi- 
cally blocked antisera- and IgG-evoked currents. Simi- 
lar receptor activation and anti-GluR3 reactivity was 
present in sera from patients with active Rasmussen's 
encephalitis, an intractable pediatric epilepsy. Thus, 
antibodies to GluR3 define a region involved in agonist 
binding and specific receptor activation. These data 
suggest that antibodies to neuronal receptors can 
function as agonists and that autoantibodies to GluRs 
may be highly specific neurotoxicants in some neuro- 
logical diseases. 
Introduction 
The excitatory amino acid neu rotransmitter glutamate has 
been implicated in the pathophysiology of epilepsy and 
neurodegenerative syndromes (Rogers et al., 1994; Choi, 
1988; Olney, 1978). The glutamate receptor (GluR) family 
is composed of closely related subunits that combine to 
form receptors that are selectively activated by agonists 
N-methyI-D-aspartate (NMDA), kainic acid (KA), or m-amino- 
3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) 
(Hollmann and Heinemann, 1994). The non-NMDA recep- 
tors are defined by at least nine cloned subunits that are 
grouped according to their relatively high sequence iden- 
tity and similar pharmacology when expressed in Xenopus 
oocytes or transfected cells (Hollmann and Heinemann, 
1994). These subunits include GluR1-4, which compose 
the AMPNKA subfamily, GluR5-7, which compose the 
KA family, and KA1 or KA2, which form high affinity KA 
binding sites when expressed in vitro and combine with 
members of the GluR5-7 family to form functional GluRs 
(Herb et al., 1992; Puchalski et al., 1994; Huntley et al., 
1993; Siegel et al., 1995). 
In two rabbits immunized with bacterially expressed 
trpE-fusion proteins containing a portion of the putative 
N-terminal extracellular domain of GluR3, behavioral char- 
acteristics indicative of seizure activity were observed 
after the rabbits developed high titers of anti-GluR3 anti- 
body. These observations uggested the hypothesis that 
antibodies directed at a Glu R subu nit directly regulate neu- 
ronal excitability by binding to and perhaps modulating 
GluRs. We therefore have analyzed the antigenic basis 
and subsequent functional consequences of anti-GluR3 
antibody interaction with GluRs. In addition to the immuni- 
zation-induced rabbit anti-GluR3 antibodies, human auto- 
antibodies to GluR3 receptor subunit proteins were also 
examined for similarities in activity and specificity. The 
human anti-GluR3 antibodies were obtained from two pre- 
viously unreported cases of biopsy-proven active Rasmus- 
sen's encephalitis, a progressive and intractable form of 
pediatric epilepsy (Rogers et al., 1994). 
Using epitope mapping and whole-cell patch-clamp re- 
cording techniques on fetal mouse cortical neurons in cul- 
ture, we demonstrate that both rabbit and human antisera 
contain antibodies directed to at least two epitopes in the 
extracellular domain of the GluR subunit GluR3, both rab- 
bit and human anti-GluR3 antisera activate a non-NMDA 
GluR current in a subset of KA-responsive neurons, and 
the active component of rabbit and human anti-GluR3 anti- 
bodies bind to, and can be blocked by, a synthetic peptide 
of GluR3. 
This is the first description of an antibody acting as a 
CNS receptor agonist. These results indicate that the ac- 
tive epitope region (amino acids 372-395) appears to be 
important in its function as a GluR agonist binding site. 
Since antibodies to a unique and defined region of the 
GluR3 receptor can function as a GluR agonist, this pre- 
sents evidence for a novel concept of the pathophysiologic 
mechanism underlying specific neuronal degeneration in 
neurological diseases. 
Results 
Reactivity of rabbit sera to GluR3 protein was demon- 
strated on transfected cells expressing GluR3 protein and 
on cortical neurons in culture. Rabbit anti-GluR3 serum 
was used to label human embryonic kidney (HEK 293) 
cells transfected with GluR1, GluR2, GluR3, GluR4, or 
GluR6. Only cells transfected with GluR3 were labeled by 
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rabbit serum prepared to GluR3 (data not shown). Com- 
parison of the G luR3 fusion protein sequence that includes 
amino acids 245-457 with the equivalent region of closely 
related GluR1 and GluR2 uncovered two regions of nota- 
ble sequence divergence, amino acids 245-274 (termed 
peptide GluR3A) and 372-395 (termed peptide GluR3B), 
respectively (Figure 1A). Peptides to these regions were 
synthetically prepared and analyzed for immunoreactivity 
with rabbit Glu R3 antiserum using an immobilized peptide 
enzyme linked immunosorbent assay (ELISA). Both rab- 
bits exhibited immunoreactivity to both peptides, although 
relative reactivity to GluR3B was greater in rabbit 5209 
than in rabbit 5210 (Figure 1 B). These results demonstrate 
that at least two peptides with low sequence identity to 
closely related GluR1 or GluR2 contain epitopes recog- 
nized by the GluR3-specific rabbit antiserum. 
To examine functional consequences of antibody bind- 
ing to GluRs, we recorded whole-cell currents from fetal 
mouse cortical neurons in culture. Sera containing anti- 
GluR3 antibody that had undergone repetitive Amicon fil- 
tration (50,000 MW cutoff to remove all glutamate and 
other small molecules) were diluted into electrophysiology 
external solution for direct application to neurons. Miniper- 
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Figure 1. Immunoreactivityto RatGluR3-Specific Protein Sequences 
(A) Alignment of the GluR3 bacterial fusion protein with the equivalent 
regions of low sequence identity designated as region A (GluR3A) 
or region B (GluR3B). Synthetic peptides were made to underlined 
sequences of Glu R3. Asterisks denote potential N-linked glycosylation 
sites. 
(B) Proportion of total GluR3-specific immunoreactivity to synthetic 
peptides GluR3A or GluR3B, respectively, in either rabbit 5209 or 
5210, as determined by ELISA. 
fusion of either rabbit 5209 or 5210 serum (1:8) to voltage- 
clamped neurons produced rapid and reversible nonde- 
sensitizing inward currents in a subset of KA-responsive 
neurons (Figure 2A). All cells responding to antibody re- 
sponded to KA. Application of the final passage filtrate 
did not evoke currents (data not shown). The number of 
positively responding cells and peak amplitudes of cur- 
rents tended to increase with age of the culture (2-5 
weeks). In cells tested also with KA, average evoked 
whole-cell current in positively responding neurons was 
0.48 _ 0.02 nA (mean _+ SEM), with a maximum of 1.6 
nA (17 of 38 KA-responsive cells). The results from rabbit 
5210 were similar, but amplitudes of evoked currents were 
about one-half that for rabbit 5209, which was consistent 
with the relative titer to the GluR3B peptide (see Figure 
1B; see below). Relative amplitudes of antibody-evoked 
currents were variable among cells when compared with 
currents evoked by 100 pM KA. Overall, the relative poten- 
cies of 1:8 GluR3 serum were less than that for 100 pM 
KA (9.8% _ 4.4% of 100 pM KA response for rabbit 5209 
antiserum; 17 cells). Antibody-evoked currents were dilu- 
tion dependent, with the relative potencies compared with 
1:8 serum dilution being 38% _ 13% at 1:16, 19% -+ 
9% at1:32, and5% _+ 4% at1:64 (Figure 2B). 
Similar experiments using control rabbit sera did not 
evoke currents. At a 1:4 dilution, preimmune serum from 
a GluR3-immunized rabbit, sera from rabbits immunized 
with a similar portion of GluR5 (amino acids 233-518), 
or sera from rabbits immunized with neuronal nicotinic 
acetylcholine receptor subunit l~2 (nAChRI~2) did not 
evoke inward currents in 3, 11, and 6 cells, respectively 
(Figure 2C). Sera from the rabbits immunized with GluR5 
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Figure 2. Rabbit Anti-GluR3 Antibody-Evoked Whole-Cell Currents 
Recorded from Voltage-Clamped Fetal Mouse Cortical Neurons in 
Culture 
Serum containing antibody (S) is from rabbit 5209 and applied at 
1 8 dilution unless otherwise noted. Ligand application isindicated by 
the dots. 
(A) Comparison of currents evoked by 100 pM kainic acid (KA) and 
by antibody (S) in two different neurons. GluR3 antibody evoked repro- 
ducible currents in a subset of neurons (A1), but little or no current 
was evoked by the antibody in other neurons (A2). 
(B) Peak current response to GluR3 antibody was dilution dependent. 
(C) Control rabbit sera consisting of antibodies raised to GluR5 (1:4 
dilution) and nAChJ32 (1:4) subunits did not evoke currents. 
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and nAChRI32 fusion proteins have been previously shown 
to contain high titers of the appropriate antibodies (Rogers 
et al., 1994; Flores et al., 1992). 
To confirm that an IgG fraction was involved in the 
evoked current response, IgG from rabbit serum was pre- 
pared using protein G-sepharose column chromatogra- 
phy. Purified rabbit 5209 IgG fraction at 1:2 dilution (calcu- 
lated to be 0.35 p.g/Id) evoked currents of similar amplitude 
when compared with rabbit 5209 sera at 1:8 dilution. Rab- 
bit 5209 sera with IgG removed (1 x concentration of col- 
umn flow-through) did not evoke currents (Figure 3A). At 
concentrations producing similar peak current ampli- 
tudes, IgG-evoked currents exhibited a different kinetic 
profile compared with the current responses evoked by 
rabbit antisera. A series of 2 s applications of the purified 
IgG fraction resulted in a decrement in peak amplitudes or 
persistent desensitization of receptors that also recovered 
slowly and incompletely (Figure 3B). This was in contrast 
to the relatively constant peak current amplitude when a 
series of serum was applied (compare Figure 2A1 and 
Figure 3B). With prolonged application (10-30 s), the IgG 
fraction response deactivated compared with the constant 
nondesensitizing response produced by antisera (Figure 
3C). Prolonged applications of purified IgG resulted in a 
deactivation of current during the application, and receptor 
responsiveness to IgG recovered slowly (data not shown). 
To test the specificity of GluR3 antibody activity on 
GluRs, rabbit serum (1:8) was mixed with GluR antago- 
nists. Antibody-evoked currents were reduced to 4% __. 
2% of control by 40 p.M 6-cyano-7-nitroquinoxaline-2,3- 
dione (CNQX; for rabbit 5209; 6 cells; Figure 4A), a non- 
NMDA GluR antagonist. Blockade of antibody-evoked cur- 
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Figure 3. Rabbit 5209 Purified IgG to GluR3 Also Evoked GluR Cur- 
rents 
Ligand application is indicated by the dots. 
(A) Purified IgG (IgG, 1:2 dilution or 0.35 lig/p.I) fraction and serum 
evoked inward currents, whereas erum with IgG removed (S - IgG) 
did not. 
(B) IgG-evoked currents desensitized with repeated application. 
(C) IgG-evoked currents deactivated with prolonged application, 
whereas erum-evoked currents changed little. 
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Figure 4. Rabbit 5209 Antibody-Evoked Currents Were Reduced by 
a Non-NMDA GluR Competitive Antagonist and by a GluR3 Specific 
Synthetic Peptide 
(A) Reduction of GluR3 antibody-evoked currents by 40 p_M CNQX 
was not voltage dependent (at -75 mV [A1] and at +75 mV [A2]). 
Serum (1:8) was applied at the dots indicated. 
(B) Rabbit 5209 antibody-evoked currents were blocked by GluR3 
receptor-specific peptide. Serum application is indicated by the dots. 
(B1) GluR3 antibody (1:8)-evoked currents were blocked by GluR3 
receptor-specific peptide to region GluR3B (0.5 p.g/p.I) but were not 
blocked by peptide to region GluR3A (0.5 p.g/pl). Serum without GluR3 
peptides also evoked current in this neuron. (B2) Peptides consisting 
of a subfractionation f GluR3B peptide (GluR3B1 and GluR3B2, 0.5 
I~g/~l each) did not block antibody-evoked currents. A mixture combin- 
ing GluR3B1 and GluR3B2 (0.5 lig/p_l each) did not reproduce the 
block produced by the full peptide GluR3B alone. 
rents by CNQX was rapid, reversible, and voltage 
independent. These findings were consistent with those 
expected for competitive antagonism of GluR agonists by 
CNQX. As expected, since no NMDA currents were 
evoked by glutamate in this paradigm, antibody-evoked 
currents were not reduced by 10 I~M MK-801 (3 cells; data 
not shown), an NMDA receptor blocker. 
To test the specificity of the antibody-evoked current 
responses further, 0.5 I~g/l~l of GluR3-specific peptides, 
denoted GluR3A or GluR3B, were incubated with GluR3 
antiserum (1:8) or IgG (0.35 I~g/~l at the 1:2 dilution) for 
15 rain at room temperature and then applied to cultured 
neurons. The mixture containing GluR3B peptide nearly 
completely blocked both the serum-evoked currents 
(5.6% _+ 2.2% of control for rabbit 5209; 17 cells; Figure 
4B1) and purified IgG-evoked currents (3 cells; data not 
shown). However, the mixture containing GluR3A peptide 
did not block antibody-evoked currents and thus served 
as a control for the GluR3B peptide (17 cells for 5209 
serum; 3 cells for 5209 IgG). Like CNQX, blockade of anti- 
body-evoked currents by GluR3B peptide was rapid, re- 
versible, and voltage independent. Further specificity was 
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tested by synthesizing two additional peptides that divided 
GluR3B peptide into essentially two halves, termed 
GluR3B1 and GluR3B2. Each peptide, either alone or in 
combination, failed to block the rabbit 5209 serum-evoked 
currents (4 cells each; Figure 4B2). Since rabbit 5209 ex- 
hibited greater immunoreactivity o GluR3B than rabbit 
5210 and was more active as an agonist, this result, taken 
together with GluR3B peptide block, indicated that this 
region of GluR3 is the immunologic target region for the 
antibody activation of this non-NMDA receptor. 
As reported previously, patients with Rasmussen's en- 
cephalitis harbor autoantibodies to GluR3, and titers of 
serum autoantibody correspond with disease severity 
(Rogers et al., 1994). Consequently, these patients pro- 
vide an opportunity to determine whether disease- 
associated human autoantibodies to GluR3 activate 
GluRs. The sera from two previously unreported patients 
with active and biopsy-proven Rasmussen's encephalitis 
(cases RW42 and HP65) were prepared as described for 
the anti-GluR3 rabbit serum. Both patients exhibited 
strong immunoreactivity towards human embryonic kid- 
ney cells transfected with cDNA encoding GluR3, but not 
GluR1, GluR2, GluR4, or GluR6 (Figure 5). 
To examine the hypothesis that human Rasmussen's 
encephalitis era containing GluR3 autoantibodies modu- 
late GluR function, we repeated the above experiments 
using human serum or IgG. Results were similar for both 
human sera, and findings are shown for RW42. Human 
sera that had undergone repetitive Amicon filtration were 
diluted into electrophysiology recording external solution 
for direct application to neurons. Miniperfusion of the two 
human sera onto voltage-clamped neurons produced 
rapid and reversible inward cationic currents in a subset 
of neurons similar to rabbit 5209 or 5210 sera (shown for 
RW42 in Figure 6A). Application of the final passage filtrate 
(fourth passage from the 50,000 MW cutoff filter) did not 
evoke currents, demonstrating that glutamate and other 
possible small GluR agonists were removed. For the hu- 
man serum RW42 (1:6 dilution), current responses were 
observed in 13 of 17 neurons tested. For human serum 
RW42, average evoked whole-cell currents in positively 
responding neurons was 0.88 ± 0.31 nA, with a maximum 
of 1.6 nA at the 1:6 dilution (13 responding cells). The 
results from the other human serum HP65 were similar, 
but peak currents were smaller when compared with 
RW42 at equivalent dilutions. Amplitudes of serum- 
evoked currents were smaller when compared with cur- 
rents evoked by 100 I~M KA in the same cell. In cells tested 
with both antibody and KA, those responding to antibody 
also responded to KA (11 cells), but some cells responded 
to KA and not to serum (6 cells). 
Experiments using direct application of human control 
sera (1:4-8 dilution) from healthy volunteers (three individ- 
uals, 4-8 cells each) did not evoke currents (data not 
shown). In addition, sera (1:4-8 dilution) from seven cases 
of confirmed paraneoplastic neurological syndromes (23 
total cells) and three cases of neurodegenerative syn- 
dromes (15 total cells) did not evoke GluR currents (data 
not shown). A mixture of Rasmussen's encephalitis patient 
serum (1:4) and glutamate (100 I~M) did not result in a 
enhancement of glutamate-evoked currents (8 cells; data 
not shown), as had been seen previously with anti-GluR5 
Rabbit 
Serum 
RE Patient 
RW 42  
RE Patient 
HP 65 
Figure 5. Immunoreactivity of Human Anti-GluR3 Sera 
Immunoreactivity of sera from two biopsy-confirmed human cases (RW42 and HP65) with active Rasmussen's encephalitis toward HEK 293 cells 
that were transfected with either GluR1, GluR2, GluR3, GluR4, or GluR6. Rabbit serum prepared to bacterial fusion protein of the respective GluR 
subunits erved as the positive control (see Experimental Procedures). Staining of the transfected cells by control serum was not observed (data 
not shown). The sera of both patients exhibited staining of GluR3-transfected cells but not in cells transfected with the other GluR subunits. 
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Figure 6, Human Sera Containing Anti-GluR3 Antibody Also Evoked 
Whole-Cell Currents Recorded from Voltage-Clamped Fetal Mouse 
Cortical Neurons in Culture 
Human serum RW42 (S) is applied at 1:6 dilution. Ligand application 
is indicated by the dots. 
(A) Human serum filtrate flow-through (FLOW, fourth passage; see 
Experimental Procedures) did not evoke current, whereas erum 
evoked a reproducible current hat was blocked by CNQX. 
(B) Purified human IgG (IgG, 0.35 I~g/p.I) from RW42 also evoked cur- 
rent, whereas erum with IgG removed (S - IgG) did not. 
(C) Human serum-evoked currents were blocked by GluR3 receptor- 
specific peptide to region GluR3B, but not by peptide to region GluR3A. 
autoantibodies found in a subset of patients with para- 
neoplastic neurodegenerative syndromes (Gahring et al., 
1995). 
To confirm that an IgG fraction was involved in the hu- 
man sera-evoked current responses, purified IgG frac- 
tions from both human sera were prepared using protein 
G-sepharose column chromatography. Purified IgG frac- 
tion from human serum evoked glutamate currents, 
whereas serum with IgG removed (column flow-through) 
did not evoke currents (Figure 6B). The human IgG current 
deactivation and desensitization responses were similar 
to those observed for the rabbits (data not shown). 
In testing pharmacologic specificity of human anti- 
GluR3 antibody activity on non-NMDA GluRs, serum- 
evoked currents were reduced to 9.7% _+ 1.7% of control 
(1:6 dilution) by 40 I~M CNQX (10 cells for both human 
sera; Figure 6A). As expected for this recording paradigm, 
human sera-evoked currents were not reduced by 10 I~M 
MK-801 (7 cells for both sera; data not shown). Like the 
rabbit antibody, blockade of human antibody-evoked cur- 
rents by CNQX was rapid, reversible, and voltage indepen- 
dent. Blockade of human antibody-evoked currents by 
the competitive antagonist CNQX suggested activity at or 
near the AMPA/KA agonist binding site. 
Similar to the rabbit sera, we tested GluR3 peptide speci- 
ficity of the human antibody-evoked current responses. 
Serum (1:6) and 0.5 lig/l~l of peptides GluR3A or GluR3B 
were incubated together 15 min at room temperature and 
then applied to cultured neurons. The mixture containing 
GluR3B peptide reduced the evoked currents from both 
human sera to 26.1% _+ 2.9% of control (12 cells for both 
sera; Figure 6C). Like for the rabbits, the mixture con- 
taining GluR3A peptide did not block antibody-evoked cur- 
rents. 
Discuss ion  
These studies demonstrate that antisera and purified IgG 
antibodies to GluR3 directly activate a subpopulation of 
GluRs. Activation of a subset of kainate-responsive neu- 
rons by the GluR3-specific antibody provides further evi- 
dence for AMPA/KA receptor diversity and potentially 
indicates the relative abundance of functional GluR3- 
containing receptors in different neurons. As an agonist 
ligand, the activation and relaxation kinetics of the GluR3 
antibody also were relatively rapid, suggesting that anti- 
body association and dissociation with the receptor were 
relatively rapid. The receptor activation was blocked by 
the competitive antagonist CNQX, thus indicating that the 
antibody epitope interacted with the AMPA/KA binding or 
an agonist binding site of the receptor. Blockade of anti- 
body activity by CNQX also suggests that the antibody 
activation of the receptor was not due nonspecific interac- 
tions with the receptor channel protein. The finding that 
the GluR3B peptide (amino acids 372-395) interferes with 
antibody activation of GluRs lends further support to the 
hypothesis that this antibody functions as a highly selec- 
tive GluR agonist. Furthermore, this peptide region of 
GluR3 may function in agonist ligand binding and confer 
ligand-specific pharmacology to a receptor subclass of 
GluRs. However, this region may not be the specific gluta- 
mate binding site because of its sequence diversity in the 
GluR family, but rather may contribute somehow in the 
binding of specific ligands and subsequent activation of 
the receptor. Mutations of amino acid residues in a region 
just distal to the GluR3B region have been identified to 
alter ECso values for glutamate agonists acting at the 
mouse al  (GluR1) subunit (Uchino et al., 1992). Alter- 
ations in agonist potency also were found using chimeric 
reconstructions of regions in rat GluR subunits just distal to 
the GluR3B region (Stern-Bach et al., 1994). These findings 
lend further support to the importance of this vicinity of 
the receptor sequence as a putative agonist binding site. 
Interestingly, the IgG- and serum-evoked currents were 
observed to have different deactivation and desensitiza- 
tion characteristics. The different GluR kinetic responses 
observed for IgG versus antisera are reminiscent of the 
differences in kinetics observed for currents evoked by 
AMPA (rapidly desensitizing) versus KA (nondesensitiz- 
ing) when either is applied to the same receptor. The etiol- 
ogy of this difference in kinetics is presently unclear, and 
its detailed study requires more rapid ligand delivery, ow- 
ing to the rapidly desensitizing response. The observed 
differences in kinetics may be due to an undetermined 
cofactor in the sera, alterations to the antibody during the 
preparation, or loss of different clones of antibody during 
the IgG purification process. A cofactor lost in the IgG 
purification may act differently on these receptors, similar 
to the interesting effects of cyclothiazide in AMPA recep- 
tors (Patneau et al., 1993; Partin et al., 1994). However, 
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application of the IgG column flow-through with the puri- 
fied IgG fraction to two neurons did not grossly alter the 
desensitizing IgG current response kinetics. Although it 
is possible that the igG was altered physically during its 
purification, the IgG fraction still activated currents that 
were blocked by GluR3B. 
Other regions of GluRs have been demonstrated to be 
important in agonist activity. Alterations in GluR agonist 
potency and pharmacology have been demonstrated to 
occur from two alternatively spliced versions of subunits 
GluR1-4, termed flip and flop (Sommer et al., 1990; Partin 
et al., 1994). This alternatively spliced sequence occurs 
considerably further downstream from the GluR3B se- 
quence at a location preceding the fourth transmembrane 
region of a previously proposed four transmembrane GluR 
topology model. In this four transmembrane model, the 
flip/flop region lies intracellularly, but recently proposed 
three transmembrane models place this region extracellu- 
larly (Wo and Oswald, 1994; Hollman et al., 1994). The 
observation that the anti-GluR3 antibody was blocked by 
CNQX suggests that the Glu R3B and flip/flop regions inter- 
act in some way to play a role in agonist binding. The 
tertiary structu re of these two distant regions of the recep- 
tor may somehow fold to form one or more binding pock- 
ets. Alternatively, these separate regions may be indepen- 
dent agonist binding sites similar to that as proposed for 
GABAA receptors activated by GABA versus pentobarbital 
(Amin and Weiss, 1993). Interestingly, a recently de- 
scribed second site for nuclear RNA editing that occurs 
immediately preceding the flip/flop sequences of GluR2-4 
only affects kinetics of receptor desensitization (Lomeli et 
al., 1994). It is possible the GluR3B agonist binding region 
and the flip/flop and RNA-edited regions interact o regu- 
late activation, deactivation, or desensitization properties. 
Whether these regions physically interact or act indepen- 
dently remains to be resolved. 
The finding that GluR3 antisera activate GluRs indicates 
that the antibodies could contribute directly to the develop- 
ment of seizure-like activity in the rabbits through binding 
and activation of the target GluR. Recently, autoantibodies 
to a specific GluR subunit, GluR3, have been detected in 
sera of patients with active Rasmussen's encephalitis, a 
particularly severe form of pediatric epilepsy (Rogers et 
al., 1994). Removal of anti-GluR3 antibodies by plasma- 
phoresis correlated with a reduced frequency of seizures 
in a case studied. In the present study, the active rabbit 
and human anti-GluR3 antibodies were demonstrated to 
have similar physiological properties and antigenic speci- 
ficity. Activation of GluRs by GluR3 autoantibodies found 
in Rasmussen's encephalitis as shown here suggests that 
a pathologic mechanism for seizures and cell loss in these 
patients is due to GluR excitation and-neuronal excitotoxic- 
ity. These findings suggest that an autoimmune process 
directed at and activating GluRs containing the subunit 
GluR3 may play a role in the pathophysiological processes 
of Rasmussen's encephalitis and refractory seizures. 
Although direct modulation of the function of a CNS neu- 
ronal receptor by antibody has not been reported pre- 
viously, antibodies are known to act directly upon other 
receptor systems in human disease. In Grave's disease, 
antibodies simulate the action of thyroid-stimulating hor- 
mone by activating the thyroid-stimulating hormone recep- 
tor. Nicotinic acetylcholine receptors at the neuromuscular 
junction are well-known antibody targets, and in physio- 
logic studies, myasthenic serum has been described to 
block channels with long open duration (Schuetze et al., 
1985). Similarly, in Lambert-Eaton syndrome, antibodies 
block calcium channel function (Kim and Neher, 1988). 
Although in vivo evidence is lacking, our results suggest 
that binding of CNS neuronal ion channel receptor anti- 
bodies to GluRs may potentially modulate GluR channel 
function by acting as highly specific agonists, such as in 
Rasmussen's encephalitis. In the diseases external to the 
CNS, however, autoantibodies have relatively free access 
to their target antigen. Our present concept of the CNS 
blood-brain barrier fails to accommodate the ready pas- 
sage of all but a minute amount of antibody from the blood 
to neuronal tissues (Juhler and Neuwelt, 1989). Therefore, 
the possibility that focal disruption of the blood-brain bar- 
rier, perhaps following trauma or infection, in a region that 
provides access of autoantibodies to the appropriate pi- 
tope on the target receptor would seem feasible. This sce- 
nario would account for the focal nature of the immune 
lesion and would also suggest that in other regions of the 
brain where the blood brain barrier is intact, particularly 
the other brain hemisphere, autoantibody fails to gain ac- 
cess to the target antigen and is spared. Consequently, 
at least three independent events could be hypothesized 
to initiate and perpetuate the disease state: first, disruption 
of the blood brain barrier by trauma or possibly infection; 
second, the presence or ability to produce the GluR3B or 
related autoantibodies; and third, the presence or display 
of GluR3 on the neuron in a form that can be accessed 
by the immune system. A "three-hit" model would also be 
consistent with the rare incidence of this disease. 
Thus, we have shown that antibodies to GluR3 reveal 
a specific peptide region of the GluR that plays a role in 
agonist binding and activation of GluRs, as well as confer 
ligand-specific pharmacology to a Glu R receptor subclass. 
These data are the first to show that induced antibodies 
and autoantibodies to a defined region of neuronal recep- 
tors function as a receptor agonist. This study also sup- 
ports the concept that these GluR autoantibodies are 
candidates for highly specific excitotoxins or neuro- 
modulators. Thus, autoimmunity argeted against a subset 
of GluR epitopes may be a pathophysiological mechanism 
for specific neuronal loss in conditions such as epilepsy 
and neurodegenerative disease syndromes. 
Experimental Procedures 
Peptide Synthesis 
The peptides corresponding toGluR3A (H2N-NNENPMVQQFIQRWV- 
RLDEREFPEAKNAPY-COOH) or GluR3B (H2N-NEYERFVPFSDQ- 
QISN DSSSSEN R K-COOH) were synthesized as am ides on a corn mer- 
cially available t ntagel resin with an Applied Biosystems 430A peptide 
synthesizer based on the Fmoc Synthesis Protocol including HBTU 
activation (Kopke et al., 1993). Peptides were cleaved from the resin 
with mixtures of trifluoracetic a id and water and pu rifled with reversed- 
phase high pressure liquid chromatography on C18 columns, em- 
ploying radients of increasing acetonitril concentrations in an aque- 
ous medium. Peptides were characterized with plasma desorption 
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mass spectroscopy (Bioion 20), and amino acid ana!ysis confirmed 
the purity and peptide composition. Molecular weights were found to 
deviate <1% from the expected values. A tyrosine was added to the 
C-terminus of GluR3A and a lysine to GluR3B to facilitate coupling to 
a carrier without interfering with the N-terminal sequence. Peptides 
GluR3B1 (H2N-NEYERFVPFSDQQ-COOH) and GluR3B2 (H2N- 
SDQQISNDSSSSENRK-COOH) were synthesized in a similar fashion 
at the University of Utah Peptide Synthesis facility. 
GluR Transfection 
HEK 293 ceils were transfected transiently with expression plasmids 
containing either the cDNA for GluR1, GluR2, GluR3, GluR4, or GluR6 
by the calcium phosphate method, fixed with 2% paraformaldehyde, 
and visualized as described (Rogers et al., 1994; Siegel et al., 1995). 
Positive controls in all experiments included the rabbit polyclonal anti- 
serum prepared to bacterial fusion proteins expressing a portion of 
the putative extracellular domain from the respective GluR subunit 
(Rogers et al., 1991, 1994). The rabbit serum used to identify these 
subunits are designated as: GluR1, 5011 (El 1); GluR2, 285; GluR3, 
5209; GluR4, C74; and GluR5-7, 5211 or 5255. Serum dilutions for 
immunized rabbits were 1:1000 and 1:500 for human sera. Negative 
controls included healthy human serum and serum from five patients 
with paraneoplastic neurodegenerative syndrome (data not shown), 
which exhibited no immunoreactivity o GluR3. 
ELISA 
GluR3A or GluR3B peptide, respectively, was added to Immulon 4 
ELISA dishes in 50 ~1 containing 20 ~g/ml peptide and allowed to 
adsorb overnight at 4°C in a humidified chamber. Peptide was re- 
moved, the wells washed with PBS, and the peptide was then blocked 
for nonspecific protein adsorption with 50 ~1 of PBS supplemented to 
3% bovine serum albumin/0.02% Tween 20 (block solution) for 2-4 
hr at room temperature or overnight at 4°C. Plates were then washed 
with PBS/0.02% Tween 20 with an ELISA plate washer, and serum 
samples from either rabbit 5209 or 5210 diluted from 1:4000 to 
1 : 10,000 were added to a subset of wells in PBS. Plates were incubated 
for 2 hr at room temperature, washed with PBS, and secondary anti- 
body (peroxidase-conjugated anti-rabbit IgG, Jackson Laboratories) 
diluted to 1:7500 in PBS was added for 1 hr at room temperature. 
Plates were washed with PBS and developed with 2,2'-azine-bis(3- 
ethylbenzthioline-6-sulfonic acid) (1 mg/ml in Mcllvaines buffer, 0.1 M 
sodium phosphate/0.05 M citrate buffer [pH 4.6]) and 0.005% HzO2. 
Development was monitored at 405 nm on an ELISA reader (Molecular 
Devices). 
Neuronal Cell Culture 
Neuronal cultures from fetal (E14-16) mouse cortex were prepared 
as previously described on poly-L-lysine coated 35 mm Falcon dishes 
(Skeen et al., 1993). Cultures were fed every other day using a growth 
medium consisting of DMEM, 10% horse serum, 30 mM glucose, and 
0.5 mM glutamine. Arabinosylcytosine was added for 1 day during the 
first week in culture to suppress growth of nonneuronal cells. 
Electrophysiology 
Electrophysiological experiments were performed on 2-5 week old 
cultures at room temperature. External bath solution consisted of 145 
mM NaCI, 1.5 mM KCI, 1 mM CaCI2, 1 mM MgCI2, 10 mM Na-HEPES, 
and 10 mM glucose (pH 7.4; 320 mOsm adjusted with sucrose). Inter- 
nal pipette solution consisted of 153 mM CsCI, 10 mM Cs-HEPES, 
4 mM MgCI2, and 5 mM EGTA (pH 7.35; - 300 mOsm). Solutions were 
designed for measurement of predominantly sodium inward currents 
and to block NMDA receptor currents when neurons were voltage- 
clamped at -75 mV. No current was evoked by 100 ~M NMDA with 
1 ~M glycine using this paradigm (data not shown). To block other 
currents, 0.2-1 I~M tetrodotoxin, 10 ~M picrctoxin, and 100 nM strych- 
nine were added to the external solution. External solution was per- 
fused continuously at -2 -3  ml/min, and the culture dish maintained 
a volume of -2  ml. Ligands were applied to cells by 2 s pressure 
ejection using blunt miniperfusion pipettes ( -20  ~m diameter and 
matched for diameter) about 100 ~m from the cell. Pipettes were kept 
out of the bath solution until immediately before application and re- 
moved from the bath immediately after application. Miniperfusion pi- 
pettes were filled and the contents ejected three times with ligand 
solution to reduce effects of protein binding to glass. Recordings were 
obtained with an Axon Instruments 200A amplifier using borosilicate 
glass electrodes (2.5-4 M~). Membrane currents were filtered at 500 
Hz and digitized at 2 kHz (Frequency Devices and Axon Instruments 
Digidata 1200). KA, MK-801, and CNQX were from RBI; TTX, picro- 
toxin, strychnine, NMDA, glycine, and salts were from Sigma. 
For filtration, serum (50 p.I) was diluted 1:9 in external solution buffer 
used for electrophysiology and added to an Amicon Microcon micro- 
concentrator filter unit 50 (50,000 MW cutoff) and centrifuged at 10,500 
rpm in an IEC microfuge until the volume was reduced to less than 
100 ~1 (approximately 8 min). This procedure was repeated four times 
to remove small molecules such as glutamate and transfer larger se- 
rum components uch as antibody into electrode buffer for application 
to cells. The final centrifugation was continued until the original serum 
volume of 50 I~1 was achieved. This volume was defined as 1 x concen- 
tration, and dilutions in external recording solution for experiments 
were made from this concentration. Filtered sera or purified IgG li- 
gands were kept on ice until immediately before use and diluted as 
1 part of 1 x concentration to y parts external solution (designated 
1 :y dilution). Rabbit and human IgG were purified from whole serum 
using GammaBind G Sepharose (Pharmacia LKB Biotechnologies) 
column chromatography according to manufacturers directions. IgG 
was diluted into external recording solution from this 1 x concentra- 
tion. Column flow-through was termed serum with IgG removed. 
Human Sera 
Serum was obtained from two previously unreported cases of patholog- 
ically proven Rasmussen's encephalitis. RW42 is a 12-year-old girl 
diagnosed with active disease by brain biopsy and currently treated 
with gabapentin. HP65 is an 8-year-old boy diagnosed with active dis- 
ease by subpial cortical resection and currently treated with phenytoin 
and valproic acid. The initials used to distinguish these patients reflect 
randomized codes used for laboratory identification. 
Acknowledgments 
This work was supported by grants from the National Institutes of 
Health National Institute of Neurological Diseases and Stroke 
(NS31519) to R. E. T., the American Federation for Aging Research 
to L. C. G., and by grants from the National Institutes of Health 
(NS30990), the Esther A. and Joseph Klingenstein Foundation, and 
the PEW Charitable Trust to S. W. R. The authors thank the following 
individuals: Drs. M. Miller and T. Barren for gracious contribution of 
patient sera, J. Tingey for her excellent issue culture, H. S. White for 
donations of culture supplies, K. Eckart for peptide construction, and 
S. Heinemann for early support and reading of the manuscript. 
The costs of publication of this article were defrayed in part by 
the payment of page charges. This article must therefore be hereby 
marked "advertisement" in accordance with 18 USC Section 1734 
solely to indicate this fact. 
Received December 27, 1994; revised February 3, 1995. 
References 
Amin, J., and Weiss, D. S. (1993). GABA-A receptor needs two homolo- 
gous domains of the beta subunit for activation by GABA but not by 
pentobarbital. Nature 366, 565-9. 
Choi, D. W. (1988). Glutamate neurotoxicity and diseases of the ner- 
vous system. Neuron 1,623-634. 
Flores, C. M., Rogers, S. W., Pabreza, L, Wolf, B., and Kellar, K. J. 
(1992). Immunoprecipitation and characterization of the high affinity 
nicotine binding site in the brain. Mol. Pharmacol. 42, 31-37. 
Gahring, L. C., Twyman, R. E., Greenlee, J., and Rogers, S. W. (1995). 
Autoantibodies to neuronal glutamate receptors in patients with para- 
neoplastic neurodegenerative syndrome enhance receptor activation. 
Mol. Med., in press. 
Herb, A., Burnashev, N., Werner, P., Sakmann, B., Wisden, W., and 
Seeburg, P. H. (1992). The KA-2 subunit of excitatory amino acid recep- 
tors shows widespread distribution in brain and forms ion channels 
with distantly related subunits. Neuron 8, 775-785. 
Neuron 
762 
Hollmann, M., and Heinemann, S. F. (1994). Cloned glutamate recep- 
tors. Annu. Rev. Biochem. 1731-108. 
Hollmann, M., Maron, C., and Heinemann, S. (1994). N-glycosylation 
site tagging reveals a three transmembrane domain topology for the 
glutamate receptor GluR1. Neuron 13, 1331-1343. 
Huntley, G. W., Rogers, B. W., Moran, T., Janssen, W., Archin, N., 
Vickers, J. C., Cauley, K., Heinemann, S. F., and Morrison, J. H. (1993). 
Selective distribution of kainate receptor subunit immunoreactivity in 
monkey neocortex revealed by a monoclonal antibody which recog- 
nizes glutamate receptor subunits GluR5/6/7. J. Neurosci., 13, 2965- 
2981. 
Juhler, M., and Neuwelt, E. A. (1989). The blood-brain barrier and the 
immune system. In Implications of the Blood-Brain Barrier and Its 
Manipulation, Volume 1, E. A. Neuwelt, ed. (New York: Plenum Press). 
Kim Y., and Neher, E. (1988). IgG from patients with Lambert-Eaton 
syndrome blocks voltage-dependent calcium channels. Science 239, 
405-408. 
Kopke, A. K., Bonk, I., Sydow, S., Menke, H., and Spiess, J. (1993). 
Characterization of the NR1, NR2A, and NR2C receptor proteins. Pro- 
tein Sci. 2, 2066-2076. 
Lomeli, H., Mosbacher, J., Melcher, T., Hoger, T., Geiger, J. R. P., 
Kunre, T., Monyer, H., Higuchi, M., Bach, A., and Seeburg, P. H. 
(1994). Control of kinetic properties of AMPA receptor channels by 
nuclear RNA editing. Science 266, 1709-1713. 
Otney, J. W, (1978). Neurotoxicity of excitatory amino acids. In Kainic 
Acid as a Tool in Neurobiology, E. G. McGeer, J. W. Olney, and 
P. L. McGeer (New York: Raven), pp. 95-171. 
Partin, K. M., Patneau, D. K., and Mayer, M. L. (1994). Cyclothiazide 
differentially modulates desensitization of a-amino-3-hydroxy-5- 
methyl-4-isoxazoleprionic acid receptor splice variants. Mol. Pharma- 
col. 46, 129-138. 
Patneau, D. K., Ladisiav, V., and Mayer, M. L. (1993). Hippocampal 
neurons exhibit cyclothiazide-sensitive rapidly desensitizing re- 
sponses to kainate. J. Neurosci. 13, 3496-3509. 
Puchalski, R. B., Louis, J. C., Brose, N., Traynelis, S. F., Egebjerg, 
J. E., Kukekov, V., Wenthold, R. J., Rogers, S. W., Lin, F., Moran, T., 
Morrison, J. H., and Heinemann, S. F. (1994). Selective RNA editing 
and subunit assembly of native glutamate receptors. Neuron 13, 131- 
147. 
Rogers, S. W., Hughes, T. E., Hollmann, M., Gasic, G. P., Deneris, 
E. S., and Heinemann, S. F. (1991). The characterization and localiza- 
tion of the glutamate receptor subunit GluR1 in the rat brain. J. Neu- 
rosci. 11, 2713-2724. 
Rogers, S. W., Andrews, P. I., Gahring, L. C., Whisenand, T., Cauley, 
K., Crain, B., Hughes, B. E., Heinemann, S. F., and McNamara, J. O. 
(1994). Autoantibodies to glutamate receptor GluR3 in Rasmussen's 
encephalitis. Science 265, 648-652. 
Schuetze, B. M., Vicini, S., and Hall. Z. W. (1985). Myasthenic serum 
selectively blocks acetylcholine receptors with long channel open 
times at developing rat endplates. Proc. Natl. Acad. Sci. USA 82, 
2533-2537. 
Siegel, S. J., Janssen, W. G., Tullai, J. W., Rogers, S. W., Moran, 
T., Heinemann, S. F., and Morrison, J. H. (1995). Distribution of the 
excitatory amino acid receptor subunits GluR2(4) in monkey hippocam- 
pus and colocalization with subunits GluR5-7 and NMDARI. J. Neu- 
rosci., in press. 
Skeen G. W., Twyman, R. E, and White H. S. (1993). The dihydropyri- 
dine nitrendipine modulates N-methyI-D-aspartate receptor channel 
function in mammalian neurons. Mol. Pharmacol. 44, 443-450. 
Sommer, B,, Keinanen, K., Verdoorn, T. A., Wisden, W., Burnashev, 
N., Herb, A., Kohler, M., Takagi, T., Sakmann, B. and Seeburg, P. H. 
(1990). Flip and flop: a cell-specific functional switch in glutamate- 
operated channels of the CNS. Science 249, 1580-1585. 
Stern-Bach, Y., Bettler, B., HarUey, M., Sheppard, P. O., O'Hara, 
P. J., and Heinemann, S. F. (1994). Agonist selectivity of glutamate 
receptors is specified by two domains structurally related to bacterial 
amino acid-binding proteins. Neuron 13, 1345-1357. 
Uchino, S., Sakimura, K. Nagahari, K., and Mishina, M. (1992). Muta- 
tions in a putative agonist binding region of the AMPA-selective gluta- 
mate receptor channel. FEBS Lett. 308, 253-257. 
Wo, Z. G., and Oswald, R. E. (1994). Transmembrane topology of 
two kainate receptor subunits revealed by N-glycosylation. Proc. Natl. 
Acad. Sci. USA 91, 7154-7158. 
